New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
15:40 EDTAMGNAmgen announces Phase 2 results of Vectibix study
Amgen announced results from the Phase 2 PEAK study that reinforce the improved overall survival, OS, benefit of panitumumab, Vectibix, when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab, Avastin, plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer, mCRC. The data was presented today at the 50th Annual Meeting of the American Society of Clinical Oncology,ASCO, in Chicago.The data presented at ASCO was an extended analysis of the PEAK study that supports the use of panitumumab in combination with FOLFOX for patients with wild-type RAS mCRC. In this exploratory analysis, patients who received panitumumab plus FOLFOX and were then treated with a VEGF inhibitor-based treatment had a median OS improvement of 41.3 months. By comparison, patients who received bevacizumab plus FOLFOX and were then treated with an anti-EGFR inhibitor-based treatment, had a median OS improvement of 29.0 months. For both arms, outcomes were similar to those observed in the overall treated population with wild-type RAS mCRC. "The initial PEAK data reinforce the potential importance of panitumumab for select patients, but we wanted to evaluate whether this benefit was dependent on administration with FOLFOX and if other subsequent treatments might impact survival outcomes," said Fernando Rivera, M.D., Medical Oncology Department, Hospital Universitario Marques de Valdecilla, Santander, Spain, and a lead investigator in the study. "These data suggest that a front-line treatment strategy with panitumumab in combination with FOLFOX may offer clinical benefit in patients with wild-type RAS metastatic colorectal cancer compared to bevacizumab-based regimens in this treatment setting."
News For AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
08:04 EDTAMGNWest Pharmaceutical's Daikyo Crystal Zenith selected by Amgen
Subscribe for More Information
February 10, 2016
07:15 EDTAMGNLeerink to hold a conference
Subscribe for More Information
February 8, 2016
15:59 EDTAMGNU.K. cost regulator reverses stance on Amgen's Repatha, PharmaTimes says
The U.K.'s National Institute for Health and Care Excellence has reversed its prior decision barring patients from accessing Amgen's cholesterol treatment Repatha, reports PharmaTimes. The agency will now allow use of the drug, alone or in combination with other therapies, for various classes of patients, though only at a 140mg biweekly dose and only as long as the company continues to offer certain discounts, the report noted. Reference Link
February 5, 2016
09:26 EDTAMGNLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:03 EDTAMGNAmgen resumed with a Market Perform at Leerink
Leerink analyst Geoffrey Porges resumed coverage of Amgen with a Market Perform rating and $179 price target.
February 4, 2016
19:15 EDTAMGNAmgen reinitiated with a Market Perform at Leerink
Target $179.
16:28 EDTAMGNAmgen reports BLINCYTO study met primary endpoint, stopped early for efficacy
Amgen announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival was met in the Phase 3 TOWER study. The randomized, open-label TOWER study evaluated the efficacy of BLINCYTO versus standard of care in adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The independent data monitoring committee recommended, and Amgen has accepted, that the study end early for efficacy. The BLINCYTO adverse events observed in the TOWER study were consistent with the known safety profile of BLINCYTO. Secondary endpoints are currently being evaluated.
16:02 EDTAMGNAmgen says trial of Repatha meets co-primary endpoints
Subscribe for More Information
February 3, 2016
08:57 EDTAMGNPullback in biotech makes M&A more attractive, says UBS
UBS analyst Andrew Peters noted the pullback in small and mid-cap biotechs and said a consequence of the lower valuations may be an increased appetite for M&A by the larger firms. Peters noted Gilead (GILD) commented on its earnings call that "there's no question" the pullback has made M&A more attractive. UBS said with valuations so far off their highs, the question remains whether management and boards will accept deals at such depressed levels.
08:48 EDTAMGNWorkday appoints Diana McKenzie as Chief Information Officer
Subscribe for More Information
February 2, 2016
08:53 EDTAMGNPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
February 1, 2016
08:25 EDTAMGNAlder pullback Friday a buying opportunity, says Leerink
Subscribe for More Information
January 29, 2016
13:38 EDTAMGNAmgen wins right to allege willful infringement in Praluent suit, Markman says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use